ERBB2 and breast cancer: Interestingly, in two studies stratifying BCBM patients into HR+, HR-/HER2+ and HR-/HER2-, no significant difference in the median time interval between BC and BM diagnosis [94], or first BM treatment [89] were observed, across BC subtypes.